Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025
Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price cuts for Ozempic and Wegovy, and fresh enthusiasm around its next‑generation obesity candidate amycretin. As of 20:48 UTC on 26 November 2025, Novo Nordisk’s U.S.-listed ADRs traded at $48.79, up about 3.7% on the day, with intraday trading between $46.79 and $49.02 and volume near 15 million shares.
